Amneal Pharmaceuticals upgraded by JP Morgan with a new price target
$AMRX
Biotechnology: Pharmaceutical Preparations
Health Care
JP Morgan upgraded Amneal Pharmaceuticals from Underweight to Neutral and set a new price target of $9.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2025 | $9.00 → $12.00 | Neutral → Overweight | Analyst |
| 9/6/2024 | $9.00 | Underweight → Neutral | JP Morgan |
DEFA14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
DEF 14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
144 - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) will present at the Barclays 27th Annual Global Healthcare Conference on March, 12, 2025. Chirag Patel, Co-Chief Executive Officer and President, will participate in a fireside chat at 11:00 AM ET. A live webcast of the fireside chat will be accessible on the Company's website at https://investors.amneal.com. A replay of the webcast will be available following the event. About Amneal Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within
Denosumab biosimilar candidates reference Prolia® and XGEVA® Amneal looks to expand portfolio to six biosimilars across eight product presentations by 2027 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, and mAbxience ("mAbxience") today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics Licensing Application (BLA) for two proposed denosumab biosimilars referencing Prolia® and XGEVA®. mAbxience is a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma. Fresenius Kabi is an operating company of Fresenius. The FDA has assigned a target action date in the four
‒ Full Year 2024 Performance Met or Exceeded All Financial Guidance Metrics – ‒ Q4 2024 Net Revenue of $731 million; GAAP Net Loss of $31 million; Diluted Loss per Share of $0.10 ‒ ‒ Q4 2024 Adjusted Net Income(1) of $40 million, Adjusted EBITDA(1) of $155 million; Adjusted Diluted EPS(1) of $0.12 ‒ ‒ Full Year 2024 Net Revenue of $2.79 billion; GAAP Net Loss of $117 million; Diluted Loss per Share of $0.38 ‒ ‒ Full Year 2024 Adjusted Net Income(1) of $187 million; Adjusted EBITDA(1) of $627 million; Adjusted Diluted EPS(1) of $0.58 ‒ ‒ Provides 2025 Financial Guidance of $3.0 to $3.1 billion in net revenue and $650 to $675 million in Adjusted EBITDA(1)(2) – Amneal Pharmaceuticals,
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
SC 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
- Celebrating Amneal's recent listing on the Nasdaq Stock Exchange Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, today announced that Chirag and Chintu Patel, Co-founders and Co-Chief Executive Officers, will ring the Nasdaq closing bell on Tuesday, April 2, 2024. "As entrepreneurs who founded Amneal in 2002, we are pleased to join the esteemed roster of Nasdaq-listed companies. Today Amneal is a growing global pharmaceutical leader with a diverse portfolio of essential medicines that help make healthy possible. Our focus on patient access and affordability allows us to improve countless lives, and our commitment to innovation a
Ms. Autor will further HIC's role as a sought-after advisor to global life sciences organizations Healthcare Innovation Catalysts, Inc. (HIC), a leading provider of regulatory affairs, clinical advisory, quality, compliance, federal partnership, and strategic advisory services to global life sciences organizations, announced today that Deborah M. Autor, former Deputy Commissioner of the U.S. Food and Drug Administration (FDA), has joined the firm as its first Chief Executive Officer. In this role, Ms. Autor will build on HIC's deep bench of cross-functional technical expertise, furthering the company's role as a sought-after advisor in both the private and public sectors. This press rele
- Nasdaq move will be effective on December 27, 2023 Amneal Pharmaceuticals, Inc. ("Amneal") (NYSE:AMRX) today announced that it will transfer its stock exchange listing to the Nasdaq Stock Market ("Nasdaq") from the New York Stock Exchange ("NYSE"). The Company expects the Nasdaq listing to occur on December 27, 2023 and will continue to trade under the current symbol "AMRX". Upon transferring, Amneal will become part of the Nasdaq Composite Index and Nasdaq Biotechnology Index. "We are pleased to join the community of global pharmaceutical companies listed on Nasdaq. We would also like to thank the NYSE for supporting the company over the last five years since our initial listing," sa
‒ Full Year 2024 Performance Met or Exceeded All Financial Guidance Metrics – ‒ Q4 2024 Net Revenue of $731 million; GAAP Net Loss of $31 million; Diluted Loss per Share of $0.10 ‒ ‒ Q4 2024 Adjusted Net Income(1) of $40 million, Adjusted EBITDA(1) of $155 million; Adjusted Diluted EPS(1) of $0.12 ‒ ‒ Full Year 2024 Net Revenue of $2.79 billion; GAAP Net Loss of $117 million; Diluted Loss per Share of $0.38 ‒ ‒ Full Year 2024 Adjusted Net Income(1) of $187 million; Adjusted EBITDA(1) of $627 million; Adjusted Diluted EPS(1) of $0.58 ‒ ‒ Provides 2025 Financial Guidance of $3.0 to $3.1 billion in net revenue and $650 to $675 million in Adjusted EBITDA(1)(2) – Amneal Pharmaceuticals,
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this here. The acc
‒ Q3 2024 Net Revenue of $702 million; GAAP Net Loss of $0.2 million; Diluted Loss per Share of $0.00 ‒ ‒ Adjusted EBITDA of $158 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Affirms 2024 Full Year Guidance ‒ Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced its results for the third quarter ended September 30, 2024. "Q3 was an excellent quarter where we continued to drive strong financial results across our diversified business and we announced three strategic actions to solidify our long-term growth. First, we launched CREXONT® for the treatment of Parkinson's disease. Second, we announced our collaboration with Metsera, Inc. to leverage Amneal's exp
Analyst upgraded Amneal Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously
JP Morgan upgraded Amneal Pharmaceuticals from Underweight to Neutral and set a new price target of $9.00
RBC Capital Mkts resumed coverage of Amneal Pharmaceuticals with a rating of Sector Perform and set a new price target of $5.00